Captopril alleviates lung inflammation in SARS-CoV-2-infected hypertensive mice  

作　　者：Wen-Cong Gao Xin Ma Peng Wang Xiao-Yan He Yong-Tang Zheng Feng-Liang Liu Chang-Bo Zheng 

机构地区：[1]School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products,Kunming Medical University,Kunming,Yunnan 650500,China [2]Key Laboratory of Animal Models and Human Diseases Mechanisms of Chinese Academy of Sciences,Center for Biosafety Mega-Science,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,Yunnan 650223,China [3]Kunming National High-Level Biosafety Research Center for Non-Human Primates,Center for Biosafety Mega-Science,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,Yunnan 650107,China

出　　处：《Zoological Research》2021年第5期633-636,共4页动物学研究（英文）

基　　金：supported by the National Key R&D Program of China(2020YFC0842000);National Natural Science Foundation of China(81960662);Science and Technology Department of Yunnan Province(202001AS070034)。

摘　　要：Severe acute respiratory syndrome coronavirus 2(SARS-Co V-2)is the etiologic agent responsible for the global coronavirus disease 2019(COVID-19)pandemic.Numerous studies have demonstrated that cardiovascular disease may affect COVID-19 progression.In the present study,we investigated the effect of hypertension on viral replication and COVID-19 progression using a hypertensive mouse model infected with SARS-Co V-2.Results revealed that SARS-Co V-2 replication was delayed in hypertensive mouse lungs.In contrast,SARS-Co V-2 replication in hypertensive mice treated with the antihypertensive drug captopril demonstrated similar virus replication as SARS-Co V-2-infected normotensive mice.

关 键 词：HYPERTENSIVE INFECTED INFLAMMATION 

分 类 号：R563.1[医药卫生—呼吸系统]